alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
**Exhibit 23.1**

 

**Consent of Independent Registered Public Accounting Firm**

 

We consent to the incorporation by reference in the Registration Statements (Form S-8 No. 333-13405 and No. 333-81023) pertaining to theAmended and Restated 1995 Equity Participation Plan of Ambassadors International, Inc. of our reports dated March 4, 2005, with respect to the consolidated financial statements and schedule of Ambassadors International, Inc., AmbassadorsInternational, Inc. management’s assessment of the effectiveness of internal control over financial reporting, and the effectiveness of internal control over financial reporting of Ambassadors International, Inc., included in this Annual Report(Form 10-K) for the year ended December 31, 2004. 

 

Our audits also included thefinancial statement schedule of Ambassadors International, Inc. listed in Item 15(a). This schedule is the responsibility of Ambassadors International, Inc.’s management. Our responsibility is to express an opinion based on our audits. In ouropinion, as to which the date is March 4, 2005, the financial statement schedule referred to above, when considered in relation to the basic financial statements taken as a whole, presents fairly in all material respects the information set forththerein. 

 

/s/    ERNST & YOUNG LLP 

 

Irvine, California 

March 14, 2005
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7970 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7970

To require direct-to-consumer advertisements for prescription drugs and 
  biological products to include truthful and not misleading pricing 
                              information.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             April 11, 2024

  Ms. Williams of Georgia (for herself and Ms. Porter) introduced the 
   following bill; which was referred to the Committee on Energy and 
  Commerce, and in addition to the Committee on Ways and Means, for a 
 period to be subsequently determined by the Speaker, in each case for 
consideration of such provisions as fall within the jurisdiction of the 
                          committee concerned

_______________________________________________________________________

                                 A BILL

 
To require direct-to-consumer advertisements for prescription drugs and 
  biological products to include truthful and not misleading pricing 
                              information.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Plain Prescription Prices Act''.

SEC. 2. REGULATING ADVERTISEMENTS FOR PRESCRIPTION DRUG AND BIOLOGICAL 
              PRODUCT PRICES.

    (a) In General.--Not later than one year after the date of the 
enactment of this Act, the Secretary of Health and Human Services, 
acting through the Administrator of the Centers for Medicare & Medicaid 
Services (referred to in this section as the ``Administrator''), shall 
promulgate regulations requiring each direct-to-consumer advertisement 
on television (including broadcast, cable, streaming, and satellite 
television) for a prescription drug or biological product for which 
payment is available under title XVIII or XIX of the Social Security 
Act to include a textual statement, which shall be truthful and not 
misleading, indicating the list price, as determined on the first day 
of the quarter during which the advertisement is being aired or 
otherwise broadcast, for a typical 30-day regimen or typical course of 
treatment (whichever is most appropriate).
    (b) Determinations.--In promulgating regulations under subsection 
(a), the Administrator shall determine--
            (1) whether such regulations should apply with respect to 
        additional forms of advertising;
            (2) the manner and format of textual statements described 
        in such subsection;
            (3) appropriate enforcement mechanisms; and
            (4) whether such textual statements should include any 
        other price information, as appropriate.
                                 <all>
```
Editorial Note on Part 886
Editorial Note: Nomenclature changes to part 886 appear at 73 FR 35341, June 23, 2008.

§ 886.1655 Ophthalmic Fresnel prism. ( a ) *Identification.* An ophthalmic Fresnel prism is a device that is a thin plastic sheet with embossed rulings which provides the optical effect of a prism. The device is intended to be applied to spectacle lenses to give a prismatic effect.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 886.9. The device is also exempt from the current good manufacturing practice requirements of the quality system regulation in part 820 of this chapter, with the exception of § 820.180, with respect to general requirements concerning records, and § 820.198, with respect to complaint files.
[52 FR 33355, Sept. 2, 1987, as amended at 53 FR 35605, Sept. 14, 1988; 66 FR 38812, July 25, 2001]
<TABLE> <S> <C>

<ARTICLE>     5
<LEGEND>  THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED
  FROM THE CONSOLIDATED BALANCE SHEET AS OF APRIL 4, 1998 AND THE
  CONSOLIDATED STATEMENT OF OPERATIONS FOR THE THREE MONTHS ENDED 
  APRIL 4, 1998 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH 
  FINANCIAL STATEMENTS.
<MULTIPLIER>  1,000
       
<S>                                     <C>
<PERIOD-TYPE>                           3-MOS
<FISCAL-YEAR-END>                       JAN-02-1999
<PERIOD-END>                            APR-04-1998
<CASH>                                    43,377 
<SECURITIES>                               5,200
<RECEIVABLES>                             57,205
<ALLOWANCES>                               8,765
<INVENTORY>                               38,936
<CURRENT-ASSETS>                         173,865
<PP&E>                                   117,347
<DEPRECIATION>                            82,987 
<TOTAL-ASSETS>                           218,460
<CURRENT-LIABILITIES>                     42,513
<BONDS>                                        0
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                      22
<OTHER-SE>                               171,809
<TOTAL-LIABILITY-AND-EQUITY>             218,460
<SALES>                                   80,750 
<TOTAL-REVENUES>                          80,750
<CGS>                                     56,904
<TOTAL-COSTS>                             56,904
<OTHER-EXPENSES>                               0
<LOSS-PROVISION>                          (1,042)
<INTEREST-EXPENSE>                           146
<INCOME-PRETAX>                            3,075
<INCOME-TAX>                               3,075
<INCOME-CONTINUING>                        3,075
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                               2,029
<EPS-PRIMARY>                               0.09
<EPS-DILUTED>                               0.09
        

</TABLE>
**Exhibit 99.5**

 

**ANNUALSTATEMENT OF COMPLIANCE**

 

**TARGETRECEIVABLES CORPORATION**

 

**TARGETCREDIT CARD OWNER TRUST 2005-1**

 

The undersigned, a dulyauthorized representative of Target Receivables Corporation, as administratorof the Target Credit Card Owner Trust 2005-1, pursuant to the Section 3.9 ofthe Indenture, dated as of November 9, 2005, between Target Credit Card OwnerTrust 2005-1, as Issuer, and Wells Fargo Bank, National Association, asIndenture Trustee, does hereby certify that:

 

1.               Capitalizedterms used in this certificate have the meanings as set forth in the Indenture.

 

2.               Theundersigned is an officer of Target Receivables Corporation.

 

3.               Asof the date hereof, the undersigned has made a review of the Issuer’sactivities during the year.

 

4.               Asof the date hereof, to the best knowledge of the undersigned, the Issuer hascomplied with all conditions and covenants in all material respects under theIndenture.

 

IN WITNESSWHEREOF, the undersigned has duly executed this statement on this 31st day of March,2006.

 
| ** ** | **TARGET  RECEIVABLES CORPORATION,**                              |
|------------|-------------------------------------------------------------------|
| ** ** | **as  Administrator of Target Credit Card**                       |
|       | **Owner  Trust 2005-1,**                                          |
|       |                                                              |
|       | **By:**                                                           | **/s/  Terrence J. Scully** |   |
|       | **    Name:  Terrence J. Scully**             |
| ** ** | **    Title:  Vice President & Director** |

 

----
```

[Federal Register Volume 75, Number 42 (Thursday, March 4, 2010)]
[Notices]
[Page 9997]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4604]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF STATE

[Public Notice 6913]

Determination and Waiver Regarding the Sixth Proviso under the 
Heading ``Economic Support Funds'' in the Department of State, Foreign 
Operations, and Related Programs Appropriations Act, 2009 (Div. H, Pub. 
L. 111-8) Relating to Assistance for Afghanistan

    Pursuant to the authority vested in me as Secretary of State, 
including by Presidential Delegation No. 2007-29 of August 27, 2007, I 
hereby determine that it is in the national security interests of the 
United States to make available $200,000,000 appropriated under the 
heading Economic Support Funds in the Department of State, Foreign 
Operations, and Related Programs Appropriations Act, 2009 (Div. H, Pub. 
L. 111-8), without regard to the restriction in the sixth proviso under 
that heading.
    This determination shall be reported to the Congress promptly and 
published in the Federal Register.

    Dated: October 15, 2009.
Hillary Rodham Clinton,
 Secretary of State.
[FR Doc. 2010-4604 Filed 3-3-10; 8:45 am]
BILLING CODE 4710-17-P
```
J~~Z~D STq?.~

iP 

YZ UNITED STATES ENVIRONMENTAL PROTECTION AGENCY 

WASHINGTON, D.C. 20460 

qt PROt"-G~ 2 

MAY 13 20"" 

OFFICE OF 

AIR AND RADIATION 

Mr. J.R. Stroble 

Director, National TRU Program 

Carlsbad Field Office 

U.S. Department of Energy 

P.O. Box 3090 

Carlsbad, NM 88221 

Dear Mr. Stroble: 

We received your letter dated May 9, 20132, requesting the U.S. Environmental Protection Agency's 

(EPA's) concurrence on the draft recertification and expansion memo to the certification of the Los 

Alamos National Laboratory (LANL). The purpose of the memo is to expand the site's certification to 

add the characterization of summary category group S4000 soils and gravel which EPA approved on 

December 31, 2012. Based on our review, we concur with CBFO's draft recertification and expansion 

memo which will allow LANL-CCP to characterize contact-handled S4000 waste. 

The EPA limitations applicable to the characterization of CH and RH TRU waste are appropriately 

included in Attachment 4 of the draft recertification and expansion memo. The waste characterization 

equipment, procedures and processes included in the memo are consistent with EPA's existing approvals 

at the site. 

Thank you for providing us with an opportunity to review the draft recertification and expansion memo 

for LANL-CCP. If you have any questions or concerns, please contact me at (202) 343-9422 or Rajani 

Joglekar at (202) 343-9462. 

Sincerely, 

Edward Feltcorn 

Center for Waste Management and Regulations 

Intemet Address (URL) • http://www.epa.gov 

Recycled/Recyclable 9 Printed with Vegetable Oil Based Inks on 100% Postconsumer, Process Chlorine Free Recycled Paper 
cc: (Electronic Distribution) 

Joe Franco, CBFO 

Marcus Pinzel, CBFO NTP 

Norma Castaneda, CBFO NTP 

Tom Morgan, CBFO NTP 

Site Documents, CBFO 

Tom Peake, EPA 

Raymond Lee, EPA
Editorial Note on Part 886
Editorial Note: Nomenclature changes to part 886 appear at 73 FR 35341, June 23, 2008.

§ 886.5905 Oral electronic vision aid. ( a ) *Identification.* An oral electronic vision aid is a battery-powered prescription device that contains an electrode stimulation array to generate electrotactile stimulation patterns that are derived from digital object images captured by a camera. It is intended to aid profoundly blind patients in orientation, mobility, and object recognition as an adjunctive device to other assistive methods such as a white cane or a guide dog.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) Clinical performance testing must demonstrate an acceptable adverse event profile, including adverse events involving the mouth, tongue, and gums and demonstrate the effect of the stimulation to provide clinically meaningful outcomes. The clinical performance testing must also investigate the anticipated conditions of use, including potential use error, intended environment of use, and duration of use.
( 2 ) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use, including simulated moisture ingress, device durability, and battery reliability.
( 3 ) Software verification, validation, and hazard analysis must be performed.
( 4 ) Analysis/testing must validate electromagnetic compatibility.
( 5 ) Analysis/testing must validate electrical safety.
( 6 ) Analysis/testing must assess and validate wireless coexistence concerns.
( 7 ) Any elements of the device that contact the patient must be demonstrated to be biocompatible.
( 8 ) Training must include elements to ensure that the healthcare provider and user can identify the safe environments for device use, use all safety features of the device, and operate the device in the intended environment of use.
( 9 ) Labeling for the trainer and user must include a summary of the clinical testing including adverse events encountered under use conditions, summary of study outcomes and endpoints, and information pertinent to use of the device including the conditions under which the device was studied (*e.g.,* level of supervision or assistance, and environment of use).
[80 FR 57092, Sept. 22, 2015]
Michigan Supreme Court

Lansing, Michigan

Bridget M. McCormack

, Chief Justice

David F. Viviano,

Chief Justice Pro Tem

Stephen J. Markman

Brian K. Zahra

Richard H. Bernstein

Elizabeth T. Clement

Megan K. Cavanagh,

Justices

I, Larry S. Royster, Clerk of the Michigan Supreme Court, certify that the

foregoing is a true and complete copy of the order entered at the direction of the Court.

December 23, 2019

b1216 

# Order

Clerk December 23, 2019

159111(19)

PEOPLE OF THE STATE OF MICHIGAN,

Plaintiff

- Appellee,

v SC: 159111

COA: 345315

Roscommon CC: 78

- 001095

- FY

DAVID MARSHALL CAMPBELL,

Defendant

- Appellant.

_________________________________________/

On order of the Court, the motion for reco nsideration of this Court’s September

10, 2019 order is considered, and it is DENIED, because we are not persuaded that

reconsideration of our previous order is warranted. MCR 7.311(G).
Editorial Note on Part 878
Editorial Note: Nomenclature changes to part 878 appear at 73 FR 35341, June 23, 2008.

§ 878.4020 Occlusive wound dressing. ( a ) *Identification.* An occlusive wound dressing is a nonresorbable, sterile or non-sterile device intended to cover a wound, to provide or support a moist wound environment, and to allow the exchange of gases such as oxygen and water vapor through the device. It consists of a piece of synthetic polymeric material, such as polyurethane, with or without an adhesive backing. This classification does not include an occlusive wound dressing that contains added drugs such as antimicrobial agents, added biologics such as growth factors, or is composed of materials derived from animal sources.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in part 807, subpart E of this chapter subject to the limitations in § 878.9.
[64 FR 53929, Oct. 5, 1999]
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               MAR-31-1998
<CASH>                                             516
<SECURITIES>                                         0
<RECEIVABLES>                                    6,473
<ALLOWANCES>                                       232
<INVENTORY>                                      6,042
<CURRENT-ASSETS>                                14,603
<PP&E>                                           5,291
<DEPRECIATION>                                   3,199
<TOTAL-ASSETS>                                  21,013
<CURRENT-LIABILITIES>                           12,845
<BONDS>                                          2,167
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            39
<OTHER-SE>                                       5,076
<TOTAL-LIABILITY-AND-EQUITY>                    21,013
<SALES>                                          9,742
<TOTAL-REVENUES>                                 9,742
<CGS>                                            7,506
<TOTAL-COSTS>                                    7,506
<OTHER-EXPENSES>                                 3,676
<LOSS-PROVISION>                                    14
<INTEREST-EXPENSE>                                 167
<INCOME-PRETAX>                                  (933)
<INCOME-TAX>                                        15
<INCOME-CONTINUING>                              (948)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     (948)
<EPS-PRIMARY>                                    (.08)
<EPS-DILUTED>                                    (.08)
        

</TABLE>
#### Crawford *et al. v.*Moorman *et al.*

No. 8733.

March 16, 1932.

Gilbert, J.

1. Error is assigned on the judgment overruling the general demurrer to the petition. It is ai'gued that the defect in the petition consisted in the failure to allege that Alexander Kemp died in possession of the land. The same question was raised by a motion for a directed verdict. The petition alleged and the evidence showed that Alexander Kemp was the common grantor of both plaintiff and defendant. “The defendant by claiming under the plaintiff’s grantor admits title in such grantor.” *Held,*no error. *Mentone*v. *Taylor,*161 *Ga.*237 (130 S. E. 527).

2. Error is assigned on the action of the court in ruling out all evidence of witnesses of the defendants “as to improvements made prior to the death of Mrs. Caroline Wells, life-tenant,” and, on motion of plaintiffs for a directed verdict, stating orally that the evidence showing the value of permanent improvements placed upon said lands prior to the death of the life-tenant was not admissible, the defendants contending that the testimony was admissible and that they were “entitled to have the value of all permanent improvements placed on the said lands by themselves and their predecessors in title, in good faith, set off against the mesne profits.” *Held,*no error. Civil Code (1910), § 5926. The will under which Mrs. Caroline Kemp Wells held a life-estate was probated on November 27, 1859. The sale by her and her husband to David Brown and Peter Crawford was on January 20, 1869. These vendees, by the exercise of the slightest diligence, could-have found from the terms of the will that Mrs. Wells did not own the fee-simple title to the land, but held only a life-estate. Moreover, in so far as the record in this case discloses, the interests of the remaindermen were not represented or considered by the judge of the superior court in passing the order for sale of the land for reinvestment. Expenditures for improvements on land by a life-tenant, or by one holding under a life-tenant and during such tenancy, are not properly chargeable against the remainder interests. Bu*rns*v. *Richardson,*145 *Ga.*430 (89 S. E. 418); *Hamilton*v. *Kinnebrew,*161 *Ga.*495 (4) (131 S. E. 470).

3. The court did not err in refusing a new trial.

*Judgment affirmed.*

*All the Justices concur.*

*630
      *J.*W. Overstreet, for plaintiffs in error.

*J. Henry Howard*and *T. J. Evans,*contra.
§ 884.6100 Assisted reproduction needles. ( a ) *Identification.* Assisted reproduction needles are devices used in in vitro fertilization (IVF), gamete intrafallopian transfer (GIFT), or other assisted reproduction procedures to obtain gametes from the body or introduce gametes, zygote(s), preembryo(s) and/or embryo(s) into the body. This generic type of device may include a single or double lumen needle and component parts, including needle guides, such as those used with ultrasound.
( b ) *Classification.* Class II (special controls) (mouse embryo assay information, endotoxin testing, sterilization validation, design specifications, labeling requirements, biocompatibility testing, and clinical testing).
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.2050 Biopotential amplifier and signal conditioner. ( a ) *Identification.* A biopotential amplifier and signal conditioner is a device used to amplify or condition an electrical signal of biologic origin.
( b ) *Classification.* Class II (performance standards).
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1715 Triiodothyronine uptake test system. ( a ) *Identification.* A triiodothyronine uptake test system is a device intended to measure the total amount of binding sites available for binding thyroid hormone on the thyroxine-binding proteins, thyroid-binding globulin, thyroxine-binding prealbumin, and albumin of serum and plasma. The device provides an indirect measurement of thyrkoxine levels in serum and plasma. Measurements of triiodothyronine uptake are used in the diagnosis and treatment of thyroid disorders.
( b ) *Classification.* Class II. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
[52 FR 16122, May 1, 1987, as amended at 64 FR 1124, Jan. 8, 1999]
* Pursuant to 5 T H C IR

. R. 47.5, the court has determined that

this opinion should not be published and is not precedent except under the limited circumstances set forth in 5 TH C IR

. R. 47.5.4.

IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 00-60699

HAROLD W. KAHLA; JULIA A. KAHLA, Petitioners-Appellants,

versus

COMMISSIONER OF INTERNAL REVENUE, Respondent-Appellee.

Appeal from the Decision of the United States Tax Court

(12318-97)

September 7, 2001

Before HIGGINBOTHAM, BARKSDALE, and STEWART, Circuit Judges.

PER CURIAM: *

We affirm for essentially the reasons stated by the Tax Court.

AFFIRMED.